Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials

Background Novel hormonal therapies have been recently investigated in non-metastatic castration-resistant prostate cancer (CRPC). We performed a meta-analysis to assess the efficacy and safety of novel hormonal therapies in non-metastatic CRPC. Materials and methods The primary outcome was metastas...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2020-07, Vol.22 (7), p.1033-1039
Main Authors: Roviello, G., Gatta Michelet, M. R., D’Angelo, A., Nobili, S., Mini, E.
Format: Article
Language:English
Subjects:
Antineoplastic Agents, Hormonal - therapeutic use
Humans
Male
Medicine
Medicine & Public Health
Oncology
Phenylthiohydantoin - analogs & derivatives
Phenylthiohydantoin - therapeutic use
Progression-Free Survival
Proportional Hazards Models
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - pathology
Pyrazoles - therapeutic use
Randomized Controlled Trials as Topic
Research Article
Survival Rate
Thiohydantoins - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Novel hormonal therapies have been recently investigated in non-metastatic castration-resistant prostate cancer (CRPC). We performed a meta-analysis to assess the efficacy and safety of novel hormonal therapies in non-metastatic CRPC. Materials and methods The primary outcome was metastasis-free survival (MFS). The secondary endpoints were overall survival (OS), time to PSA progression and safety. We planned a subgroup analysis according to the PSA doubling time (> 6 vs
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-019-02228-2